Worldwide clinical safety assessment of gadoteridol injection: An update

European Radiology

Volumn 7, Issue SUPPL. 5, 1997, Pages

  Runge, V M ^a   Parker, J R ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Bracco Research USA   (United States)

Author keywords

Contrast media, complications; Contrast media, paramagnetic; Gadolinium; Magnetic resonance (MR), contrast enhancement; Safety

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GADOTERIDOL; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SAFETY;

ADOLESCENT; ADULT; AGED; CHILD; CONTRAST MEDIA; FEMALE; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; SAFETY;

EID: 0031308932     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00006900     Document Type: Article

References (10)

1. Laniado M, Weinmann HJ, Schörner W, et al (1984) First use of GdDTPA in Man. Physiol Chem Physics Med NMR 16:157-165
2. Carr JJ (1994) Magnetic resonance contrast agents for neuroimaging: safety issues. Neuroimag Clin N Am 4: 43-54
3. Niendorf HP, Dinger JC, Haustein J, et al (1991) Tolerance data of Gd-DTPA: a review. Eur J Radiol 13: 15-20
4. LaFrance ND, Parker JR, Lucas TR, et al (1995) Clinical investigation of the safety and pharmacokinetics of gadoteridol injection in renally-impaired patients or patients requiring hemodialysis. Society of Magnetic Resonance Meeting, 19-25 August 1995, Nice, France (abstract #287)
5. Olukotun AY, Parker JR, Meeks MJ, et al (1995) Safety of gadoteridol injection: U.S. clinical trial experience. J Magn Reson Imaging 5: 17-25
6. Niendorf HP, Seifert W (1988) Serum iron and serum bilirubin after administration of Gd-DTPA dimeglumine: a pharmacologic study in healthy volunteers. Invest Radiol 23:S275-S280
7. Runge VM, Bradley WG, Brant-Zawadzki MN, et al (1991) Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 181: 701-709
8. Sze G, Brant-Zawadzki M, Haughton VM, et al (1991) Multi-center study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181: 693-699
9. McNamara MT, Greco A, Carsin M, et. al. (1995) Double-blind multicenter study comparing the efficacy, safety and tolerance of gadoteridol and gadopentetate dimeglumine as neurologic MR contrast agents. Society of Magnetic Resonance Meeting, 19-25 August 1995, Nice, France (abstract #289)
10. Tanenbaum LN (1995) Large-scale clinical evaluation of gadoteridol injection: safety, efficacy and impact on diagnosis and treatment. Society of Magnetic Resonance Meeting, 19-25 August 1995, Nice, France (abstract #290)